Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
70
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (1415 trials with phase data)• Click on a phase to view related trials
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4
- Registration Number
- NCT07216079
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Drug: SAR446597Drug: Sham Comparator
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT07215234
- Locations
- 🇺🇸
Associated Retina Consultants - Peoria - DocTrials - PPDS- Site Number : 8400011, Peoria, Arizona, United States
🇺🇸Vitreo Retinal Associates, P.A.- Site Number : 8400004, Gainesville, Florida, United States
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3000
- Registration Number
- NCT07200206
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
- Conditions
- Immunoglobulin G4 Related Disease
- Interventions
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 124
- Registration Number
- NCT07190196
- Locations
- 🇺🇸
San Jose Clinical Trials- Site Number : 8400016, San Jose, California, United States
🇺🇸Life Clinical Trials- Site Number : 8400002, Margate, Florida, United States
🇺🇸Stryde Research- Site Number : 8400011, Plano, Texas, United States
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 942
- Registration Number
- NCT07190209
- Locations
- 🇺🇸
Newport Native MD- Site Number : 8400003, Newport Beach, California, United States
🇺🇸Helix Biomedics, LLC- Site Number : 8400065, Boynton Beach, Florida, United States
🇺🇸MCR Research- Site Number : 8400004, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 299
- Next
News
AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
Sanofi Expands Decade-Long Partnership with Medidata to Accelerate Clinical Trial Development
Sanofi and Medidata announced an expansion of their 10-plus-year collaboration to leverage AI-embedded platform solutions across clinical workflows.
Inhibrx to Present Topline Results from Registrational Chondrosarcoma Trial of Ozekibart
Inhibrx Biosciences will host a webcast on October 23, 2025, to present topline results from the registrational ChonDRAgon study of ozekibart in advanced chondrosarcoma patients.
Electra Therapeutics' ELA026 Receives FDA Breakthrough Therapy and EMA Priority Designations for Rare Inflammatory Disease
Electra Therapeutics' ELA026 becomes the first investigational therapy to receive both FDA Breakthrough Therapy designation and EMA Priority Medicines designation for secondary hemophagocytic lymphohistiocytosis (sHLH).
Sanofi's Efdoralprin Alfa Achieves Primary Endpoints in Phase 2 Alpha-1 Antitrypsin Deficiency Study
Sanofi's efdoralprin alfa demonstrated statistically significant superiority over standard plasma-derived therapy in the ElevAATe phase 2 study, meeting all primary and key secondary endpoints for alpha-1 antitrypsin deficiency emphysema treatment.
Merck KGaA's Precem-TcT ADC Shows 31% Response Rate in Colorectal Cancer, Advances to Phase III
Merck KGaA's antibody-drug conjugate precemtabart tocentecan (Precem-TcT) demonstrated a 31% objective response rate in heavily pre-treated colorectal cancer patients at 2.8mg/kg dose during Phase I trials.
California Launches First State-Branded Insulin Program, Offering $55 Five-Pack to Combat High Drug Costs
California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025.
CD40-Targeted Therapies Advance Toward First Approval by 2027 with Over 35 Candidates in Clinical Development
Over 35 CD40-targeted therapies are currently in clinical trials, with the first approval expected by 2027 according to new market research.
Cincinnati Children's Develops Human Liver Organoid Platform to Predict Immune-Mediated Drug Toxicity
Researchers at Cincinnati Children's Hospital Medical Center, in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that integrates patient-specific genetics and immune responses to predict idiosyncratic drug-induced liver injury.
Dupilumab Reduces Severe COPD Exacerbations Regardless of Cardiovascular and Metabolic Comorbidities
Post hoc analysis of pooled BOREAS and NOTUS phase 3 trials demonstrates dupilumab's consistent efficacy in reducing COPD exacerbations by 31-33% regardless of cardiovascular or metabolic disease history.